Brain-Focused Startup Oyster Gets $60M to Beat the Size Problem for Small Molecule Degraders
Oyster Therapeutics’ lead program penetrates the brain to degrade pathological tau associated with Alzheimer’s disease. Eli Lilly, maker of the amyloid-targeting Alzheimer’s drug Kisunla, participated in the startup’s new financing.